Ken McNickle is sharing a terrifying health battle.
The Survivor alum—who was the runner-up on season 33 of the CBS reality show in 2016—shared he's been diagnosed with cancer, explaining how he...
JUNE 9 — Every year, June marks Cancer Immunotherapy Awareness Month — a global effort to increase public understanding of one of the most promising advances in modern cancer treatment.
Unlike conventional therapies that directly target tumours, immunotherapy works by empowering the body’s own immune system to recognise and fight cancer cells. Over the past decade, immunotherapy has transformed cancer care worldwide, offering new hope to patients with cancers that were once difficult to treat.
However, while scientific progress continues rapidly, public understanding of immunotherapy often remains limited. One of the biggest challenges in cancer awareness is combating misinformation and widespread myths. In today’s digital era, misleading health information can spread rapidly online, creating confusion and fear.
This highlights the importance of evidence-based science communication led by healthcare professionals and researchers to debunk common misconceptions:
The “Natural” Myth: Many believe that because immunotherapy uses the body’s own cells, it is a “natural” treatment without side effects. In reality, while it avoids the hair loss typically seen in chemotherapy, it can cause unique immune-related side effects where the body’s defenses become overactive.
The “Universal Cure” Myth: While revolutionary, immunotherapy is not yet a “silver bullet” for every patient. Factors like the Tumour Microenvironment (TME) can shield certain cancers, particularly solid tumours—from immune attack. This is exactly why ongoing research into enhancing CAR-T cells or CAR-NK cells are so vital.
The “Last Resort” Myth: There is a common misconception that immunotherapy is only for terminal cases. In fact, it is increasingly being used as a primary, first-line treatment to provide long-term protection and “immune memory” against cancer recurrence.
This is why cancer awareness programmes remain essential. Behind every public health campaign, educational talk, or community outreach activity is a dedicated team working to bridge the gap between scientific discoveries and public understanding. Organising these programmes requires months of planning, collaboration, and commitment from researchers, clinicians, students, and volunteers.
In addition to local outreach efforts, our experience in organising community engagement activities through laboratory tours with Cancer Research UK has provided valuable insight into how scientific communication can be made more accessible and impactful. Observing how researchers open their laboratories to the public, explain ongoing experiments, and engage visitors directly with real scientific work has been particularly inspiring. We are actively working towards adapting and implementing similar lab tour–based outreach initiatives in Northern Malaysia to strengthen public understanding of cancer research and immunology.
Cancer awareness initiatives are not simply about distributing pamphlets or setting up booths. They are about making complex medical science understandable and accessible to communities. Topics such as early detection, prevention, cancer screening, and emerging therapies like immunotherapy must be communicated clearly to help the public make informed health decisions.
As researchers in cancer immunology, we believe science should not remain confined within laboratories or academic journals. Scientific discoveries achieve their greatest impact when knowledge reaches the public.
In conjunction with Cancer Immunotherapy Awareness Month in June, our team has been actively involved in outreach and education initiatives aimed at increasing awareness about cancer immunotherapy and the role of the immune system in fighting cancer. At Pusat Kanser Tun Abdullah Ahmad Badawi, Universiti Sains Malaysia, we are also honoured that our project has received funding support from the British Society for Immunology (BSI) under the Communication and Engagement Grant. This reflects the growing international recognition of the importance of immunology education.
We are incredibly grateful for the invaluable support of the National Cancer Council (MAKNA), who have championed this BSI-funded initiative by sending dedicated volunteers and cancer survivors to participate, bridging the gap between science and lived experience. Furthermore, our close collaboration with Universiti Teknologi MARA (UiTM) Bertam, alongside the active participation of key national institution including the Malaysian Stem Cell Registry (MSCR), National Institutes of Health (NIH)— underscores the unified, academic and national effort required to advance healthcare literacy in Malaysia.
Importantly, these programmes are not only educational — they are deeply human. Conversations with cancer survivors, caregivers, patients, and families often remind organisers that awareness campaigns are ultimately about people, not just statistics. A simple discussion about symptoms, screening, or treatment options may encourage someone to seek medical attention earlier or feel less afraid of discussing cancer openly.
Cancer awareness also inspires future generations. Many students attending outreach programmes become interested in science, immunology, and biomedical research after realising how research can directly impact human lives. As immunotherapy continues to reshape the future of cancer treatment, public awareness must grow alongside scientific advancement. Education empowers communities, reduces stigma, encourages early detection, and helps society better understand the evolving landscape of cancer care.
Scientific breakthroughs may begin in laboratories, but meaningful impact happens when knowledge reaches people.
And sometimes, awareness itself can become a powerful form of hope.
*The author is from Pusat Kanser Tun Abdullah Ahmad Badawi, Universiti Sains Malaysia, and she can be contacted at fara.hassan@usm.my
* This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Sharon Stone had an instinct her previous marriage had run its course.
The Basic Instinct actress revealed that she ended her marriage because of the way her ex-husband reacted to her early 2000s...
In 2021, Miriam González, a 35-year-old from Murcia, Spain, went to the doctor because she was bleeding from her breast. She was told to relax: everything was normal. But in 2024, she was diagnosed with breast cancer. And, shortly afterward, she discovered it was metastatic, at stage four.
Caroline Kennedy is putting a spotlight on Tatiana Schlossberg.
Five months after the environmental journalist died at 35 following a battle with a rare blood cancer, the former U.S....
LONDON, June 9 — GSK has agreed to buy US-listed cancer drug developer Nuvalent for US$10.6 billion in its largest deal in more than a decade, marking a major strategic shift under new CEO Luke Miels as the British company steps up its focus on oncology.
The all-cash deal values Nuvalent at approximately US$124 per share, a 40 per cent premium to its last closing price. Shares in Nuvalent, which develops lung cancer drugs, were up about 38 per cent at US$122.10 in US premarket trade. GSK shares slipped over 3 per cent in early trading in London.
The deal marks a departure from GSK’s usual strategy of smaller “bolt-on” deals as Miels, who took over from Emma Walmsley at the start of the year, looks to convince investors the drugmaker can hit a bold target of £40 billion in annual revenue by 2031.
“It’s larger than the bracket because it was unusual,” Miels told reporters on a call, although he said GSK’s sales targets were not dependent on the acquisition. “It’s a multi-product deal... So it’s essentially three products in one.”
UBS analysts said that investors could be surprised by the size of the deal, given GSK’s normal preference for acquisitions in the US$2 billion to US$4 billion range.
Building scale in cancer treatments
Miels said the acquisition offered “significant new treatment options” for lung cancer patients and creates a platform to expand its experimental antibody-drug conjugate Ris-Rez, now in late-stage testing.
He has pledged to speed development of new medicines and target assets to strengthen GSK’s late-stage pipeline and manage the 2028 patent expiry of its key HIV medicine dolutegravir. GSK has struck two smaller deals this year since Miels took over.
In 2025, GSK saw notable growth across its oncology portfolio, with sales income across the disease area swelling by 43 per cent to just under £2 billion compared to 2024. Oncology accounts for about 6 per cent of GSK’s £32.7 billion in total sales.
Barclays analysts said the Nuvalent deal made strategic sense because it adds late-stage cancer assets in an area where GSK already operates, and could help offset the expected HIV patent cliff if approvals come on time.
GSK is also seeking to close the gap with London-listed rival AstraZeneca in cancer drugs. Oncology accounted for 44 per cent of the Anglo-Swedish group’s total sales last year.
Net of cash acquired, GSK’s aggregate investment is estimated to be US$9.4 billion, the British company said, adding that the deal is expected to add to sales and operating profit in 2027 and core earnings per share in 2029.
Multi-blockbuster potential
Miels said GSK had tracked Nuvalent for over a year after it was first identified by its oncology and business development teams, and was internally known as “Nashville”.
Nuvalent’s data at a major medical conference last week convinced him that GSK should pursue the deal, he said.
The deal adds Nuvalent’s two lead lung cancer drugs, zidesamtinib and neladalkib, to GSK’s basket of products that are close to being launched. US decisions for the drugs are expected in September and November this year.
If approved, both could launch in 2026 and GSK believes the drugs have multi-blockbuster potential. UBS analysts expect zidesamtinib to bring in nearly US$2 billion in peak annual sales.
The deal also adds an early-stage HER2 lung cancer drug and several cancer programmes still in lab-testing stages to GSK’s pipeline.
The deal, which is expected to close in the third quarter of 2026, will be funded mainly from new and existing debt facilities plus cash and could have a low single-digit percentage dilution to core earnings per share for 2026 to 2028, GSK said. — Reuters
When he got his cancer diagnosis, Los Angeles-based photojournalist David Swanson vowed, “I will get through this.”
Barry Manilow just wants to sing the old songs again.
Two months after announcing he's cancer free, the "Copacabana" singer shared a heartbreaking update amid his recovery from a "nightmare"...
If photographs could make a sound, the one Edith Sánchez keeps in a small plastic bag would play Luis Miguel’s version of Las Mañanitas. Dated September 16, 1994, the photo shows the Mexican singer hugging her as she looks at the camera. It is the only picture she has left beside the man who was her boss for more than 25 years.
Kate Middleton is detailing a cancer diagnosis’ ripple effect.
Specifically, how it impacts the loved ones of the person navigating the illness. Over a year after the Princess of Wales announced...
Login